Successful £31.1m fundraise despite challenging markets

Lighthouse | 6 March 2024

Share this note

  • Avacta has successfully raised £31.1m gross in a placing to institutional investors, and through a retail offer. Funds will be used to advance the therapeutics pipeline, in particular AVA6000 into initial Phase II studies. The institutional placing was to existing and new investors, including an EU specialist healthcare fund. Around 62.3m shares in total will be issued at a price of 50p, representing a 34% discount to the mid-market closing price on 27 February.
  • The fundraise has three elements: (1) a firm placing of 27.5m shares issued under existing authorisations to raise £13.8m gross, including 130k shares (£65k) to certain directors of the company; (2) a conditional placing of 23.9m shares to raise £11.9m gross; and (3) a retail offer, which was limited to existing shareholders, which will raise £5.4m gross. Shares as part of the firm placing were admitted on 4 March, while issuance of the remaining shares will require approval at a General Meeting on 18 March.
  • The main use of proceeds will be advancing AVA6000, which has been shown to be selectively activated at the target tumour site, resulting in lower toxicities, improved tolerability, and greater potency. Following recent additional AVA6000 data (December 2023 Update) from the seventh and final dosing cohort of Phase Ia three-weekly dosing arm, patients are being enrolled for the two-weekly arm in the US. Data will direct the format of the potentially pivotal Phase II trial (which could support initial regulatory approvals) and will include establishing a recommended Phase II dose. Dose expansions in several orphan indications, including soft tissue sarcomas, are expected to begin in H224. A Phase III trial (which would need to be initiated if AVA6000 is approved based on Phase II data) could potentially commence in 2026, subject to funding or partnering.
  • In parallel, management is exploring routes to divest its Diagnostics business in a manner that maximises shareholder value. The October 2022 £62m convertible bond was issued to support the creation of a self-sustaining integrated Diagnostics business through both acquisition and organic investment. Launch Diagnostics was acquired for £24m (October 2022 Lighthouse) and Coris Bioconcept for £7.4m (June 2023 Lighthouse). FY23 adjusted revenues are expected to be c £22m and FY24 is forecast to be c £24m, becoming EBITDA positive in H224 and cash generative in FY25.

Trinity Delta view:The upsized fundraise of £31.1m (gross), together with existing cash of £16.6m (at 1 January 2024), are expected to provide a cash runway of c 24 months (ie into early 2026) covering a number of value inflection points in AVA6000’s development pathway, which could bring opportunities for non-dilutive funding for the broader pre|CISION platform. Monetising Diagnostics through divestment would also bring in non-dilutive funding, but may, in our view, be targeted for later in this period, giving management time to embed the acquisitions, and improve the sales and profitability trajectory. As usual in such situations, we suspend our valuation and forecasts; for context our last published Avacta valuation was £672m (equivalent to 237p per share).


6 March 2024

Market Cap£166.55m
Primary exchangeAIM
Company CodeAVCT
Corporate clientYes

Company description

Avacta owns two novel technology platforms: Affimer and pre|CISION. Affimer proteins are antibody mimetics being developed as diagnostic reagents and oncology therapeutics. pre|CISION improves potency and reduces toxicity of cancer drugs by only activating them inside the tumour. Successful clinical trials would be transformative for Avacta.


Lala Gregorek
+44 (0) 20 3637 5043

Philippa Gardner
+44 (0) 20 3637 5042


Trinity Delta Research Limited (“TDRL”; firm reference number: 725161), which trades as Trinity Delta, is an appointed representative of Equity Development Limited (“ED”). The contents of this report, which has been prepared by and is the sole responsibility of TDRL, have been reviewed, but not independently verified, by ED which is authorised and regulated by the FCA, and whose reference number is 185325.

ED is acting for TDRL and not for any other person and will not be responsible for providing the protections provided to clients of TDRL nor for advising any other person in connection with the contents of this report and, except to the extent required by applicable law, including the rules of the FCA, owes no duty of care to any other such person. No reliance may be placed on ED for advice or recommendations with respect to the contents of this report and, to the extent it may do so under applicable law, ED makes no representation or warranty to the persons reading this report with regards to the information contained in it.

In the preparation of this report TDRL has used publicly available sources and taken reasonable efforts to ensure that the facts stated herein are clear, fair and not misleading, but make no guarantee or warranty as to the accuracy or completeness of the information or opinions contained herein, nor to provide updates should fresh information become available or opinions change.

Any person who is not a relevant person under section of Section 21(2) of the Financial Services & Markets Act 2000 of the United Kingdom should not act or rely on this document or any of its contents. Research on its client companies produced by TDRL is normally commissioned and paid for by those companies themselves (‘issuer financed research’) and as such is not deemed to be independent, as defined by the FCA, but is ‘objective’ in that the authors are stating their own opinions. The report should be considered a marketing communication for purposes of the FCA rules. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and it is not subject to any prohibition on dealing ahead of the dissemination of investment research. TDRL does not hold any positions in any of the companies mentioned in the report, although directors, employees or consultants of TDRL may hold positions in the companies mentioned. TDRL does impose restrictions on personal dealings. TDRL might also provide services to companies mentioned or solicit business from them.

This report is being provided to relevant persons to provide background information about the subject matter of the note. This document does not constitute, nor form part of, and should not be construed as, any offer for sale or purchase of (or solicitation of, or invitation to make any offer to buy or sell) any Securities (which may rise and fall in value). Nor shall it, or any part of it, form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The information that we provide is not intended to be, and should not in any manner whatsoever be, construed as personalised advice. Self-certification by investors can be completed free of charge at www.fisma.org. TDRL, its affiliates, officers, directors and employees, and ED will not be liable for any loss or damage arising from any use of this document, to the maximum extent that the law permits.

Copyright 2024 Trinity Delta Research Limited. All rights reserved.